We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 336

Application for an order of prohibition dismissed for formulation patent

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • March 18 2015

The Court found that Mylan’s allegations of non-infringement and obviousness were justified. As a result, the application for prohibition was

Decision of Re-Examination Board affirmed on standard of reasonableness

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • March 11 2015

The Re-examination Board found the Claims of a patent obvious in light of prior art submitted by the person requesting re-examination. In so holding

Formulation patent allegations of non-infringement, obviousness and lack of utility justified

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • March 2 2015

Servier sought a prohibition order against Apotex in relation to its DIAMICRON MR gliclazide product. The application was dismissed. The patent at

Application for an order of prohibition is dismissed

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • February 23 2015

The Court found that Teva’s allegation of obviousness was justified. As a result, the application was dismissed

Application for an order of prohibition is dismissed for a unit dose patent

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • February 23 2015

The Court found that Mylan’s allegations of lack of utility, anticipation and obviousness were justified. As a result, the application was dismissed

Appeal in NOC Proceeding dismissed as moot

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • February 9 2015

The Court of Appeal granted Teva’s motion to have an appeal from a NOC Proceeding dismissed as moot. The Respondent’s request for an oral hearing of

Other industry news: February 9 2015

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • February 9 2015

Health Canada has updated the Guidance Document: Patented Medicines (Notice of Compliance) Regulations

Finding of non-infringement upheld on appeal

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • February 9 2015

The Court of Appeal dismissed an appeal of a decision of the Court in a NOC proceeding finding that an allegation of non-infringement was justified

Order of prohibition granted in respect of use patent

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • January 26 2015

The Court found that Mylan’s allegations of lack of utility, and specifically lack of sound prediction, and obviousness-type double patenting were

Court finds claims do not cover method of medical treatment, orders that they issue

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • January 19 2015

In this decision, AbbVie brought a judicial review of a decision of the Commissioner of Patents refusing to issue its patent. The issue was whether